0001437749-24-007753 | 10-K | XBRL Viewer

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE 7 – Investments

The following table summarizes the Company’s investments as of December 31, 2023 (in thousands):

	*Amortized Cost Basis*		*Unrealized Gains*		*Unrealized Losses*			*Fair Value*
Assets:
Cash equivalents
Money market funds	$	9,704	$	—	$	—		$	9,704
Marketable securities
U.S. government	$	28,618	$	36	$	(20	)	$	28,634
Corporate bonds		6,756		2		(20	)		6,738
Commercial paper		7,094		8		(1	)		7,101
Certificates of deposit		3,988		7		—			3,995
Total marketable securities	$	46,456	$	53	$	(41	)	$	46,468
Total assets at fair value	$	56,160	$	53	$	(41	)	$	56,172

The following table summarizes the Company’s investments as of December 31, 2022 (in thousands):

	*Amortized Cost Basis*		*Unrealized Gains*		*Unrealized Losses*			*Fair Value*
Marketable securities
U.S. government	$	28,742	$	—	$	(49	)	$	28,693
Corporate bonds		2,392		—		(5	)		2,387
Commercial paper		9,417		—		(25	)		9,392
Certificates of deposit		4,112		—		(28	)		4,084
Total marketable securities	$	44,663	$	—	$	(107	)	$	44,556

The Company classifies its investments as available-for-sale, and they consist entirely of debt securities. As of December 31, 2023, the amortized cost of investments included an immaterial amount of accrued interest. As of December 31, 2023, marketable securities were in a net unrealized gain position. Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.

As of December 31, 2023, the aggregate fair value of investments held by the Company in an unrealized loss position was $22.9 million which consisted of 30 securities. The unrealized loss was primarily driven by rising interest rates. The Company does not expect to settle the debentures at a price less than the amortized cost basis of the investment; the Company expects to recover the entire amortized cost basis of the security. In accordance with the Company’s general investment strategy, the Company does not intend to sell the investments before maturity. As of December 31, 2023, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no allowance for credit losses were recognized in the period.

The Company’s investments as of December 31, 2023 mature at various dates through January 2026. The fair values of investments by contractual maturity consist of the following (in thousands):

	*December 31, 2023*		*December 31, 2022*
Maturities within one year	$	51,670	$	44,556
Maturities after one year through three years		4,502		—
Total investments	$	56,172	$	44,556

Note 18 - Related Parties (Details Textual) $ in Thousands	12 Months Ended
Note 18 - Related Parties (Details Textual) $ in Thousands	Dec. 31, 2022 USD ($)
Related Party Transaction, Amounts of Transaction	$ 0

Note 5 - Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Inventory, Current [Table Text Block]

	*December 31, 2023*		*December 31, 2022*
Raw materials ⁽¹⁾	$	4,464	$	4,676
Finished goods		2,877		2,019
Total inventories	$	7,341	$	6,695

Note 10 - Long-term Debt - Long Term Debt (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Interest expense	$ 14,715	$ 8,438
Interest expense	14,715	8,438
Pharmakon Loan [Member]
Long-term debt at closing of Pharmakon loan		100,000
Capitalized costs and discounts		(4,217)
Interest expense	14,715	8,438
Amounts paid	(13,701)	(6,685)
Carrying value of Pharmakon loan as of December 31, 2022	98,551	97,537
Interest expense	$ 14,715	$ 8,438

Note 3 - Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Loss attributable to equity holders of the Company	$ (102,244)	$ (109,783)
Weighted-average number of ordinary shares (in shares)	28,834,303	22,806,812
Loss per ordinary share (in dollars per share)	$ (3.55)	$ (4.81)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Note 7 - Investments (Details Textual) $ in Millions	Dec. 31, 2023 USD ($)
Debt Securities, Available-for-Sale, Unrealized Loss Position	$ 22.9

Note 9 - Prepaid Forward Obligation (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	May 31, 2021	Mar. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Prepaid Forward Obligation			$ 109,722	$ 98,923	$ 85,713
Other Current Liabilities [Member]
Prepaid Forward Obligation			3,000	$ 2,300
RTW Investments [Member]
Proceeds from Prepaid Forward Obligation	$ 75,000	$ 75,000
Proceeds from Prepaid Forward Arrangement, Net	$ 72,400	$ 72,400
Prepaid Forward Agreement, Minimum Future Cash Flows			$ 200,000
Prepaid Forward Agreement, Minimum Future Cash Flows, Rate (Rate)			13.00%
Prepaid Forward Obligation, Expected Cash Flows in Next Twelve Months			$ 0
RTW Investments [Member] \| Sales of Up to $200 Million [Member] \| Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		9.50%
Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales		3.50%
RTW Investments [Member] \| Sales Between $200 Million and $300 Million [Member] \| Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		3.00%
RTW Investments [Member] \| Sales Over $300 Million [Member] \| Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		1.00%
RTW Investments [Member] \| Sales Up to $200 Million with FDA Approval [Member] \| UGN-102 [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		2.50%
RTW Investments [Member] \| Sales Between $200 Million and $300 Million with FDA Approval [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		1.00%
RTW Investments [Member] \| Sales Over $300 Million with FDA Approval [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		0.50%
Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales		1.50%

Note 16 - Share-based Compensation - Number of Employee and Non-employee Options Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Granted, number of options (in shares)	530,000	410,064
Employees and Non-employees [Member]
Outstanding, number of options (in shares)	2,590,539	2,969,557
Outstanding, weighted average price per share (in dollars per share)	$ 27.05	$ 27.7
Granted, number of options (in shares)	530,000	410,064
Granted, weighted average price per share (in dollars per share)	$ 11.75	$ 7.82
Forfeited, number of options (in shares)	(268,316)	(496,417)
Forfeited, weighted average price per share (in dollars per share)	$ 27.42	$ 27.97
Exercised, number of options (in shares)	(166,427)	(292,665)
Exercised, weighted average price per share (in dollars per share)	$ 5.25	$ 5.16
Outstanding, number of options (in shares)	2,685,796	2,590,539
Outstanding, weighted average price per share (in dollars per share)	$ 25.35	$ 27.05
Vested and expected to vest (in shares)	2,685,796
Vested and expected to vest, weighted average price per share (in dollars per share)	$ 25.35
Exercisable (in shares)	1,831,743
Exercisable, weighted average price per share (in dollars per share)	$ 6.1

Note 10 - Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Long-Term Debt Instruments [Table Text Block]

Long-term debt at closing of Pharmakon loan	$	100,000
Capitalized costs and discounts		(4,217	)
Interest expense		8,438
Amounts paid		(6,685	)
Carrying value of Pharmakon loan as of December 31, 2022		97,537
Interest expense		14,715
Amounts paid		(13,701	)
Carrying value of Pharmakon loan as of December 31, 2023	$	98,551

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

Note 11 - Leases - Components of Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease cost	$ 934	$ 975
Sublease income	(224)	(224)
Variable lease cost	73	65
Lease, Cost	$ 783	$ 816

Note 10 - Long-term Debt (Details Textual) - Secured Debt [Member] - USD ($) $ in Millions		1 Months Ended
	Mar. 07, 2022	Jul. 31, 2023
Secured Long-Term Debt, Noncurrent	$ 100.0
Secured Long Term Debt, First Tranche	75.0
Secured Long Term Debt, Additional Draw	$ 25.0
Long-Term Debt, Term (Year)	5 years
Debt Instrument, LIBOR Floor	1.25%
Debt Issuance Costs, Gross	$ 4.2
Secured Overnight Financing Rate (SOFR) [Member]
Debt Instrument, Basis Spread on Variable Rate	8.25%	0.26161%

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation, Depletion and Amortization, Total	$ 802	$ 924

Note 8 - Property and Equipment

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment Disclosure [Text Block]

NOTE 8 – PROPERTY AND EQUIPMENT

Property and equipment, consists of the following as of December 31, 2023 and 2022 (in thousands):

	*December 31,*
	*2023*			*2022*
Laboratory equipment	$	464		$	452
Computer equipment and software		2,293			2,168
Furniture		612			602
Leasehold improvements		617			617
Manufacturing equipment		655			608
		4,641			4,447
Less: accumulated depreciation and amortization		(3,952	)		(3,150	)
Property and equipment, net	$	689		$	1,297

Depreciation and amortization expense was $0.8 million and $0.9 million for the years ended December 31, 2023 and 2022, respectively.

Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)	Dec. 31, 2023
Computers and Software [Member]
Useful life (Year)	3 years
Laboratory Equipment [Member] \| Minimum [Member]
Useful life (Year)	3 years
Laboratory Equipment [Member] \| Maximum [Member]
Useful life (Year)	6 years 6 months
Furniture [Member[ \| Minimum [Member]
Useful life (Year)	5 years
Furniture [Member[ \| Maximum [Member]
Useful life (Year)	16 years 6 months
Manufacturing Equipment [Member] \| Minimum [Member]
Useful life (Year)	2 years
Manufacturing Equipment [Member] \| Maximum [Member]
Useful life (Year)	10 years

Note 15 - Shareholders' Equity

12 Months Ended

Dec. 31, 2023

Equity [Text Block]

NOTE 15 – SHAREHOLDERS’ EQUITY

The Company had 100.0 million ordinary shares authorized for issuance as of December 31, 2023 and 2022. The Company had 32.5 million and 23.1 million ordinary shares issued and outstanding as of December 31, 2023 and 2022, respectively.Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors (the "Board"). Since its inception, the Board has not declared any dividends.

On July 26, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers 7,300,380 ordinary shares of the Company (“Shares”) and 5,278,776 of pre-funded warrants to purchase ordinary shares of the Company at a purchase price of $9.54 per Share or $9.539 for each ordinary share underlying a pre-funded warrant, in a private placement transaction that closed on July 28, 2023 and August 9, 2023 (the “Private Placement”) for aggregate gross proceeds of $120.0 million, before deducting fees to placement agents and financial advisors and before other expenses paid by the Company. Each pre-funded warrant has an exercise price of $0.001 per ordinary share, subject to customary adjustments, became exercisable upon original issuance and will not expire until exercised in full. The pre-funded warrants may not be exercised if the aggregate number of ordinary shares beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation. The aggregate fee paid by the Company to placement agents and financial advisors was $3.6 million, plus the reimbursement of certain expenses.

Resales of the Shares and the ordinary shares issuable upon exercise of the pre-funded warrants were registered pursuant to the Company’s registration statement on Form S-3 (File No. 333-274423) filed with the U.S. Securities and Exchange Commission (“SEC”) on September 8, 2023, which was declared effective on September 15, 2023.

On December 20, 2023, the Company issued 1,599,733 ordinary shares through a cashless conversion of 1,599,840 pre-funded warrants for the purchase of ordinary shares of the Company.

Monograph Capital Partners I, L.P. (“Monograph”), a life sciences venture firm that is affiliated with Fred Cohen, M.D., a director of the Company, purchased 1,572,327 of the Shares in the Private Placement, for an aggregate purchase price of $15.0 million. Dr. Cohen is the Chair and Chief Investment Officer of Monograph.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Note 1 - Business and Nature of Operations

12 Months Ended

Dec. 31, 2023

Nature of Operations [Text Block]

Note 1 – Business and Nature of Operations

Nature of Operations

UroGen Pharma Ltd. is an Israeli company incorporated in April 2004 (“UPL”).

UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in October 2015 and began operating in February 2016 (“UPI”).

UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s first commercial product, Jelmyto (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, clinical development of UGN-102, and raising capital to support and expand these activities.

On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.

Note 7 - Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash equivalents	$ 95,002	$ 55,408
Amortized cost basis	46,456	44,663
Unrealized gains	53	0
Unrealized losses	(41)	(107)
Fair value	46,468	44,556
Total assets at fair value	56,160
Total assets at fair value, unrealized gains	53
Total assets at fair value, unrealized losses	(41)
Total assets at fair value, fair value	56,172
Fair value	46,468	44,556
Money Market Funds [Member]
Cash equivalents	9,704
Cash equivalents, unrealized gains	0
Cash equivalents, unrealized loss	0
Cash equivalents, fair value	9,704
US Treasury and Government [Member]
Amortized cost basis		28,742
Unrealized gains		0
Unrealized losses		(49)
Fair value		28,693
Fair value		28,693
Corporate Debt Securities [Member]
Amortized cost basis	6,756	2,392
Unrealized gains	2	0
Unrealized losses	(20)	(5)
Fair value	6,738	2,387
Fair value	6,738	2,387
US Treasury Securities [Member]
Amortized cost basis	28,618
Unrealized gains	36
Unrealized losses	(20)
Fair value	28,634
Fair value	28,634
Commercial Paper [Member]
Amortized cost basis	7,094	9,417
Unrealized gains	8	0
Unrealized losses	(1)	(25)
Fair value	7,101	9,392
Fair value	7,101	9,392
Certificates of Deposit [Member]
Amortized cost basis	3,988	4,112
Unrealized gains	7	0
Unrealized losses	0	(28)
Fair value	3,995	4,084
Fair value	$ 3,995	$ 4,084

Note 7 - Investments (Tables)

12 Months Ended

Dec. 31, 2023

Marketable Securities [Table Text Block]

	*Amortized Cost Basis*		*Unrealized Gains*		*Unrealized Losses*			*Fair Value*
Assets:
Cash equivalents
Money market funds	$	9,704	$	—	$	—		$	9,704
Marketable securities
U.S. government	$	28,618	$	36	$	(20	)	$	28,634
Corporate bonds		6,756		2		(20	)		6,738
Commercial paper		7,094		8		(1	)		7,101
Certificates of deposit		3,988		7		—			3,995
Total marketable securities	$	46,456	$	53	$	(41	)	$	46,468
Total assets at fair value	$	56,160	$	53	$	(41	)	$	56,172

	*Amortized Cost Basis*		*Unrealized Gains*		*Unrealized Losses*			*Fair Value*
Marketable securities
U.S. government	$	28,742	$	—	$	(49	)	$	28,693
Corporate bonds		2,392		—		(5	)		2,387
Commercial paper		9,417		—		(25	)		9,392
Certificates of deposit		4,112		—		(28	)		4,084
Total marketable securities	$	44,663	$	—	$	(107	)	$	44,556

Investments Classified by Contractual Maturity Date [Table Text Block]

	*December 31, 2023*		*December 31, 2022*
Maturities within one year	$	51,670	$	44,556
Maturities after one year through three years		4,502		—
Total investments	$	56,172	$	44,556

Note 16 - Share-based Compensation - Outstanding and Exercisable Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Exercise price per share, lower limit (in dollars per share)	$ 8.84	$ 5.19
Exercise price per share, upper limit (in dollars per share)	$ 17.94	$ 11.88
Number of options outstanding (in shares)	2,685,796
Number of options exercisable (in shares)	1,831,743
Exercise Price Per Share Range One [Member]
Exercise price per share, lower limit (in dollars per share)	$ 0
Exercise price per share, upper limit (in dollars per share)	$ 10
Number of options outstanding (in shares)	386,064
Options outstanding, Weighted average remaining contractual life (Year)	13 years
Number of options exercisable (in shares)	152,018
Options exercisable, Weighted average remaining contractual life (Year)	12 years 2 months 19 days
Exercise Price Per Share Range Two [Member]
Exercise price per share, lower limit (in dollars per share)	$ 10.01
Exercise price per share, upper limit (in dollars per share)	$ 20
Number of options outstanding (in shares)	920,000
Options outstanding, Weighted average remaining contractual life (Year)	8 years 3 months 7 days
Number of options exercisable (in shares)	372,496
Options exercisable, Weighted average remaining contractual life (Year)	7 years 1 month 9 days
Exercise Price Per Share Range Three [Member]
Exercise price per share, lower limit (in dollars per share)	$ 20.01
Exercise price per share, upper limit (in dollars per share)	$ 30
Number of options outstanding (in shares)	455,300
Options outstanding, Weighted average remaining contractual life (Year)	6 years 1 month 9 days
Number of options exercisable (in shares)	382,797
Options exercisable, Weighted average remaining contractual life (Year)	5 years 11 months 1 day
Exercise Price Per Share Range Four [Member]
Exercise price per share, lower limit (in dollars per share)	$ 30.01
Exercise price per share, upper limit (in dollars per share)	$ 40
Number of options outstanding (in shares)	201,000
Options outstanding, Weighted average remaining contractual life (Year)	4 years 9 months 29 days
Number of options exercisable (in shares)	201,000
Options exercisable, Weighted average remaining contractual life (Year)	4 years 9 months 29 days
Exercise Price Per Share Range Five [Member]
Exercise price per share, lower limit (in dollars per share)	$ 40.01
Exercise price per share, upper limit (in dollars per share)	$ 50
Number of options outstanding (in shares)	637,432
Options outstanding, Weighted average remaining contractual life (Year)	4 years 9 months 10 days
Number of options exercisable (in shares)	637,432
Options exercisable, Weighted average remaining contractual life (Year)	4 years 9 months 10 days
Exercise Price Per Share Range Six [Member]
Exercise price per share, lower limit (in dollars per share)	$ 50.01
Exercise price per share, upper limit (in dollars per share)	$ 59.23
Number of options outstanding (in shares)	86,000
Options outstanding, Weighted average remaining contractual life (Year)	4 years 5 months 4 days
Number of options exercisable (in shares)	86,000
Options exercisable, Weighted average remaining contractual life (Year)	4 years 5 months 4 days

Note 2 - Basis of Presentation

12 Months Ended

Dec. 31, 2023

Basis of Accounting [Text Block]

Note 2 – Basis of Presentation

The Company has experienced net losses since its inception and has an accumulated deficit of $679.3 million and $577.1 million as of December 31, 2023 and 2022, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.

In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date the financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from Jelmyto product sales and develop UGN-102.

The Company believes that absent sufficient proceeds received from equity, financing, or business development transactions, the Company will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Accordingly, the Company will, over the next twelve months, require significant additional financing to continue its operations. In addition, there can be no assurances that the Company will be able to secure such additional financing if at all, on terms that are satisfactory to the Company, and in amounts sufficient to meet its needs. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Failure to successfully receive additional financing will require the Company to delay, limit or reduce product development and commercialization efforts.

Note 4 - Other Financial Information

12 Months Ended

Dec. 31, 2023

Other Financial Information [Text Block]

NOTE 4 – oTHER fINANCIAL INFORMATION

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following as of December 31, 2023 and 2022 (in thousands):

	*December 31, 2023*		*December 31, 2022*
Accounts payable	$	6,514	$	5,527
Accrued sales reserves		4,391		618
Accrued clinical expenses		1,246		2,853
Accrued research and development expenses		1,049		1,285
Accrued selling, general and administrative expenses		2,752		1,609
Accrued other expenses		586		491
Total accounts payable and accrued expenses	$	16,538	$	12,383

Interest and Other Income, Net

Interest and other income, net consisted of the following for the year ended December 31, 2023 and 2022 (in thousands):

	*Year Ended December 31,*
	*2023*		*2022*
Interest income	$	2,641	$	938
Other income, net		838		72
Total interest and other income, net	$	3,479	$	1,010

Note 19 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Text Block]

NOTE 19 – COMMITMENTS AND CONTINGENCIES

In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of December 31, 2023 and 2022. The Company does not anticipate recognizing any significant losses relating to these arrangements.

On February 25, 2024, we received a Paragraph IV Certification Notice Letter from Teva, providing notification that Teva has submitted an ANDA to the FDA seeking approval to manufacture, use or sell a generic version of Jelmyto. In the Notice Letter, Teva alleges that two of the patents listed in the FDA Orange Book for Jelmyto, U.S. Patent Numbers 9,040,074 and 9,950,069 each of which expires in January 2031, are invalid, unenforceable, or will not be infringed by Teva’s manufacture, use, or sale of the generic product described in its ANDA submission. If we are unable to maintain patent protection for Jelmyto, Jelmyto will be subject to immediate competition from generic entrants after regulatory exclusivity expires in April 2027.

Leases

See Note 11 for further discussion regarding lease commitments.

Note 6 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

			*Fair Value Measurements Using*
			*Quoted Prices*		*Significant*
			*in Active*		*Other*
	*Balance as of*		*Markets for*		*Observable*
	*December 31,*		*Identical Assets*		*Inputs*
	*2023*		*(Level 1)*		*(Level 2)*
Assets:
Cash equivalents
Money market funds	$	9,704	$	9,704	$	—
Marketable securities
U.S. government	$	28,634	$	28,634	$	—
Corporate bonds		6,738		—		6,738
Commercial paper		7,101		—		7,101
Certificates of deposit		3,995		—		3,995
Total marketable securities	$	46,468	$	28,634	$	17,834
Total assets at fair value	$	56,172	$	38,338	$	17,834

			*Fair Value Measurements Using*
			*Quoted Prices*		*Significant*
			*in Active*		*Other*
	*Balance as of*		*Markets for*		*Observable*
	*December 31,*		*Identical Assets*		*Inputs*
	*2022*		*(Level 1)*		*(Level 2)*
Marketable securities
U.S. government	$	28,693	$	28,693	$	—
Corporate bonds		2,387		—		2,387
Commercial paper		9,392		—		9,392
Certificates of deposit		4,084		—		4,084
Total marketable securities	$	44,556	$	28,693	$	15,863

Note 17 - Income Taxes - Summary of Current Income Taxes Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
U.S. Federal	$ 2,937	$ 584
U.S. State	983	1,171
Total current taxes	$ 3,920	$ 1,755

Note 3 - Significant Accounting Policies (Details Textual) $ in Millions	Dec. 31, 2023 USD ($)
Cash, Cash Equivalents, and Short-Term Investments	$ 141.5

Note 10 - Long-term Debt

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Text Block]

NOTE 10 – Long-Term Debt

On March 7, 2022, the Company entered into a loan agreement with Pharmakon for a senior secured term loan of up to $100 million in two tranches. The first tranche of $75 million was funded in March 2022. The second tranche of $25 million was funded in December 2022. The facility will mature five years from initial funding and can be prepaid in whole at the Company's discretion, at any time, subject to prepayment premiums and make-whole amounts. The loan will require interest-only payments for the first 48 months followed by principal and interest payments with interest accruing using 3-month London Inter-Bank Offered Rate (“LIBOR”) (with a 1.25% floor) plus 8.25%. On June 29, 2023, the loan agreement with Pharmakon was amended to replace the benchmark governing the interest rate with a rate based on the secured overnight financing rate ("SOFR") published by the Federal Reserve Bank of New York. Effective July 2023, the loan will accrues interest using a benchmark rate of 3-month SOFR plus a 0.26161% adjustment. The Company is not required to maintain any financial covenants.

The Company incurred financing expenses of $4.2 million which are recognized as a direct offset to the long-term debt on the Company's consolidated balance sheets. These debt issuance costs are amortized over the term of the debt using the effective interest method, and are recorded in the consolidated statements of operations as “Interest expense".

The following table shows the activity with respect to the carrying value of the long-term debt, in thousands:

Long-term debt at closing of Pharmakon loan	$	100,000
Capitalized costs and discounts		(4,217	)
Interest expense		8,438
Amounts paid		(6,685	)
Carrying value of Pharmakon loan as of December 31, 2022		97,537
Interest expense		14,715
Amounts paid		(13,701	)
Carrying value of Pharmakon loan as of December 31, 2023	$	98,551

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Note 2 - Basis of Presentation (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Retained Earnings (Accumulated Deficit)	$ (679,348)	$ (577,104)

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Note 11 - Leases (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Note 11 - Leases (Details Textual) - USD ($) $ in Thousands	Oct. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Nov. 29, 2019
Lessee, Operating Lease, Liability, to be Paid		$ 1,821	$ 2,887
Operating Lease, Impairment Loss		0
Operating Lease, Liability		1,663	2,527
Sublease Income		224	$ 224
Company Offices in Israel [Member]
Lessee, Operating Lease, Liability, to be Paid		500
Lease Agreement for Office in Los Angeles, California [Member] \| UroGen Pharma Inc. [Member]
Operating Lease, Impairment Loss	$ 200
Operating Lease, Liability		100
Sublease Income		100
Lease Agreement for Office in Princeton, New Jersey [Member] \| UroGen Pharma Inc. [Member]
Operating Lease, Liability		$ 1,200
Lessee, Operating Lease, Term of Contract (Month)				38 months

Note 16 - Share-based Compensation - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding, RSU (in shares)	690,955	753,274
Granted, RSU (in shares)	854,249	445,980
Vested and released, RSU (in shares)	(293,626)	(374,293)
Forfeited, RSU (in shares)	(152,894)	(134,006)
Outstanding, RSU (in shares)	1,098,684	690,955

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 95,002	$ 55,408
Marketable securities	41,966	44,556
Restricted cash	821	813
Accounts receivable	15,443	12,704
Inventories	5,673	4,325
Prepaid expenses and other current assets	10,281	11,101
Total current assets	169,186	128,907
Non-current assets:
Property and equipment, net	689	1,297
Restricted deposit	225	223
Right-of-use assets	1,671	2,452
Marketable securities	4,502	0
Other non-current assets	2,038	2,740
Total Assets	178,311	135,619
Current liabilities:
Accounts payable and accrued expenses	16,538	12,383
Employee related accrued expenses	10,814	8,257
Other current liabilities	3,860	3,276
Total current liabilities:	31,212	23,916
Non-current liabilities:
Prepaid forward obligation	109,722	98,923
Long-term debt	98,551	97,537
Long-term lease liabilities	844	1,586
Uncertain tax positions liability	3,194	3,018
Total Liabilities	243,523	224,980
Commitments and Contingencies (Note 19)
Shareholders' Deficit:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2023 and 2022; 32,490,119 and 23,129,953 shares issued and outstanding as of December 31, 2023 and 2022, respectively	89	63
Additional paid-in capital	614,035	487,787
Accumulated deficit	(679,348)	(577,104)
Accumulated other comprehensive income (loss)	12	(107)
Total Shareholders' Deficit	(65,212)	(89,361)
Total Liabilities and Shareholders' Deficit	$ 178,311	$ 135,619

Note 11 - Leases

12 Months Ended

Dec. 31, 2023

Lessee, Operating Leases [Text Block]

NOTE 11 – Leases

Operating Leases

The Company had the following office and laboratory facility leases as of December 31, 2023:

•

In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company’s offices located in Israel, in order to increase the office space rented and to extend the rent period for an additional three years until August 2022. In July 2022, the Company signed a lease extension agreement for the Company’s offices located in Israel, extending the term of the lease through September 2025. The Company's remaining contractual obligation under this lease is approximately $0.5 million as of December 31, 2023.

•

In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminated in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company’s remaining contractual obligation under this lease is approximately $0.1 million as of December 31, 2023. In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of January 1, 2020 and terminating at the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises at the end of November 2019. The remaining rental payments to be received over the lease term is approximately $0.1 million as of December 31, 2023. The Company accounts for the sublease as on operating lease in accordance with ASC 842.

•

In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 with an original lease term of 38 months, expiring January 31, 2023. In June 2022, the Company signed a lease extension for the Princeton office, extending the term of the lease through January 31, 2026. The Company’s remaining contractual obligation under this lease is approximately $1.2 million as of December 31, 2023.

In addition, the Company has other operating office equipment and vehicle leases. The Company’s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company’s leases do not contain any residual value guarantees or material restrictive covenants. The Company’s leases expire at various dates from 2024 through 2026, with varying renewal and termination options.

The components of lease cost for the year ended December 31, 2023 and 2022 were as follows (in thousands):

	*Year Ended December 31, 2023*			*Year Ended December 31, 2022*
Operating lease cost	$	934		$	975
Sublease income		(224	)		(224	)
Variable lease cost		73			65
	$	783		$	816

The amounts recognized as of December 31, 2023 and 2022 were as follows (in thousands):

	*Year Ended December 31, 2023*		*Year Ended December 31, 2022*
Right-of-use assets	$	1,671	$	2,452
Long-term lease liabilities		844		1,586
Other current liabilities		819		941

As of December 31, 2023, no impairment losses have been recognized.

Supplemental information related to leases for the periods reported is as follows (in thousands, except for lease term and discount rate amounts):

	*Year Ended December 31, 2023*			*Year Ended December 31, 2022*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		1,169			1,195
Right-of-use assets obtained in exchange for new operating lease liabilities		122			2,165
Weighted-average remaining lease term of operating leases (in years)		1.92			2.73
Weighted-average discount rate of operating leases		10.21	%		10.25	%

As of December 31, 2023, maturities of lease liabilities were as follows (in thousands):

	*Operating Leases*
Years ending December 31,
2024	$	938
2025		825
2026		58
Total future minimum lease payments	$	1,821
Less: Interest		(158	)
Present value of lease liabilities	$	1,663

As of December 31, 2022, maturities of lease liabilities were as follows (in thousands):

	*Operating Leases*
Years ending December 31,
2023	$	1,146
2024		904
2025		788
2026		49
Total future minimum lease payments	$	2,887
Less: Interest		(360	)
Present value of lease liabilities	$	2,527

Subleases

As of December 31, 2023, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis were as follows (in thousands):

	*Operating Leases*
Years ending December 31,
2024	$	49
Total future minimum sublease payments	$	49

As of December 31, 2022, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands):

	*Operating Leases*
Years ending December 31,
2023	$	251
2024		49
Total future minimum sublease payments	$	300

Note 17 - Income Taxes - Changes in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ (129,601)	$ (100,619)
Changes during the year	(13,965)	(28,982)
Balance	$ (143,566)	$ (129,601)

Note 12 - Revenue From Product Sales - Net Product Sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 82,713	$ 64,357
Jelmyto [Member]
Revenue	$ 82,713	$ 64,357

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

Note 18 - Related Parties

12 Months Ended

Dec. 31, 2023

NOTE 18 – RELATED PARTIES

See Note 15 for discussion regarding an affiliated investor in the Private Placement for the year ended December 31, 2023. There were no related party transactions for the year ended December 31, 2022.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows From Operating Activities
Net loss	$ (102,244)	$ (109,783)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	802	924
Inventory Obsolescence	0	870
Accrued financing on prepaid forward obligation	11,504	14,007
(Accretion) on marketable securities	(1,034)	(498)
Share-based compensation	9,343	10,580
Amortization (accretion) of discount on long-term debt	1,014	1,754
Amortization of right-of-use assets	903	893
Changes in operating assets and liabilities:
Inventory	(1,348)	(362)
Accounts receivable	(2,739)	(987)
Prepaid expenses and other current assets	820	(3,626)
Other non-current assets	702	(1,269)
Accounts payable and accrued expenses	4,155	281
Employee related accrued expenses	2,557	1,309
Other current liabilities	0	(703)
Lease liabilities	(987)	(1,125)
Uncertain tax positions	176	176
Net cash used in operating activities	(76,376)	(87,559)
Cash Flows From Investing Activities
Purchases of marketable securities	(49,832)	(63,009)
Maturities of marketable securities	49,073	64,323
Purchases of property and equipment	(194)	(254)
Net cash (used in) provided by investing activities	(953)	1,060
Cash Flows From Financing Activities
Proceeds from exercise of options into ordinary shares	873	1,511
Proceeds from issuance of long-term debt	0	95,783
Proceeds from pre-funded warrant issuance, net	48,700	0
Proceeds from ordinary share issuance, net	67,358	0
Issuance cost related to at-the-market issuances	0	(160)
Net cash provided by financing activities	116,931	97,134
Increase in Cash and Cash Equivalents	39,602	10,635
Cash, Cash Equivalents and Restricted Cash at Beginning of Year	56,221	45,586
Cash, Cash Equivalents and Restricted Cash at End of Year	95,823	56,221
Supplemental Disclosures of Non-Cash Activities
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 122	$ 2,165

Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 1,437	$ 1,314
Accruals	23,368	13,430
Utilizations	(18,834)	(13,307)
Balance	5,971	1,437
Government Sponsored Programs Reserves [Member]
Balance	590	373
Accruals	11,110	6,967
Utilizations	(10,638)	(6,750)
Balance	1,062	590
Other Reserves [Member]
Balance	847	941
Accruals	12,258	6,463
Utilizations	(8,196)	(6,557)
Balance	$ 4,909	$ 847

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 82,713	$ 64,357
Cost of revenue	9,361	7,654
Gross profit	73,352	56,703
Operating expenses:
Research and development expenses	45,614	52,906
Selling, general and administrative expenses	93,274	82,838
Operating loss	(65,536)	(79,041)
Financing on prepaid forward obligation	(21,552)	(21,559)
Interest expense on long-term debt	(14,715)	(8,438)
Interest and other income, net	3,479	1,010
Loss before income taxes	(98,324)	(108,028)
Income tax expense	(3,920)	(1,755)
Net Loss	(102,244)	(109,783)
Statements of Comprehensive Loss
Net loss	(102,244)	(109,783)
Other comprehensive income (loss)
Unrealized gain (loss) on investments	119	(82)
Comprehensive Loss	$ (102,125)	$ (109,865)
Net loss per ordinary share - basic and diluted (in dollars per share)	$ (3.55)	$ (4.81)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	28,834,303	22,806,812

Note 8 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Table Text Block]

	*December 31,*
	*2023*			*2022*
Laboratory equipment	$	464		$	452
Computer equipment and software		2,293			2,168
Furniture		612			602
Leasehold improvements		617			617
Manufacturing equipment		655			608
		4,641			4,447
Less: accumulated depreciation and amortization		(3,952	)		(3,150	)
Property and equipment, net	$	689		$	1,297

Note 14 - Employee Rights Upon Retirement

12 Months Ended

Dec. 31, 2023

Employee Rights Upon Retirement [Text Block]

NOTE 14 – EMPLOYEE RIGHTS UPON RETIREMENT

In Israel, the Company is required by law to make severance payments upon dismissal of an employee or upon termination of employment in certain other circumstances.

The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not included in the Company’s financial position.

The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law, 5723-1963. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan, as defined above.

Note 13 - License and Collaboration Agreements (Details Textual) - MD Anderson [Member] - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2023
Collaboration Agreement, Term (Year)	3 years
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross		$ 2

Note 3 - Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Significant Accounting Policies [Text Block]

Note 3 – Significant Accounting Policies

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results may differ from those estimates. As applicable to the consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.

Functional Currency

The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.

Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the consolidated statements of operations as “Interest and other income, net.”

Cash and Cash Equivalents; Marketable Securities

The Company presents all highly liquid investments with an original maturity of three months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.

Cash and cash equivalents and marketable securities totaled $141.5 million as of December 31, 2023. The Company accounts for its investments, which include cash equivalents and marketable securities, as available-for-sale in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses are recorded as a component of interest and other income, net. The cost of securities sold is based on the specific-identification method.

Certain short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.

Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.

The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.

Income Taxes

The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.

The Company follows a two-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note 17 for further discussion related to income taxes.

Inventory

The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto, the Company commenced capitalization of inventory at the receipt of FDA approval.

The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.

Property and Equipment

Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Property and equipment are depreciated over the following useful lives (in years):

	*Useful Lives*
Computers and software		3
Laboratory equipment		3 - 6.5
Furniture		5 - 16.5
Manufacturing equipment		2 - 10

Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.

Prepaid Forward Obligation

The Company is party to a transaction with RTW Investments (the “RTW Transaction”) in which the Company received funds to support the continued launch of Jelmyto and the development of UGN-102 in return for tiered, future cash payments based on net sales of Jelmyto and UGN-102, if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the consolidated balance sheets. The subsequent measurement for the liability follows the accounting principles defined in ASC Topic 835-30, “Imputation of Interest”. See Note 9 for further discussion related to the prepaid forward obligation.

Long-Term Debt

The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (“Pharmakon”). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note 10 for further discussion related to long-term debt.

Leases

The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.

The Company accounts for leases in accordance with ASC Topic 842, “Leases”. The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as right-of-use assets on the consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as long-term lease liabilities on the consolidated balance sheets.

Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the consolidated statements of operations in the same line item as expense arising from fixed lease payments.

The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.

Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment,” to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.

Revenue

Product sales from Jelmyto are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of Jelmyto are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenue recognized includes gross revenue and management’s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340B drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company’s copay assistance program, and Medicare refunds for discarded drug, which are estimated based on the Company’s historical experience.

Research and Development Expenses

Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.

Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. For performance stock units (“PSUs”), cost is measured at the grant date based on the fair value of the award and is recognized over any relevant service period as expense when the achievement of the performance condition is probable. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) or a PSU equals the closing price of the Company’s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, “Compensation—Stock Compensation”.

The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.

Pre-funded Warrants

The Company issued pre-funded warrants in connection with a private placement transaction that are accounted for as a freestanding equity-linked financial instrument that meets the criteria for equity classification under ASC 480, “Distinguishing Liabilities from Equity,” and ASC 815, “Derivatives and Hedging.” Accordingly, the Company classifies the pre-funded warrants as a component of permanent shareholders’ equity within additional paid-in capital and records them at the issuance date using a relative fair value allocation method. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated the net sales proceeds from the private placement transaction proportionately to the ordinary shares and pre-funded warrants. See Note 15 for further discussion related to the private placement transaction.

Net Loss per Ordinary Share

Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.

For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.

The Company’s pre-funded warrants requires the holder to pay nominal consideration to receive the Company’s ordinary shares and are therefore considered outstanding shares in determining basic and diluted earnings per share in accordance with ASC Topic 260, “Earnings per Share”.

The following table summarizes the calculation of basic and diluted loss per ordinary share for the periods presented (in thousands, except share and per share amounts):

	*Year Ended December 31,*
	*2023*			*2022*
Basic and diluted:
Loss attributable to equity holders of the Company	$	(102,244	)	$	(109,783	)
Weighted-average number of ordinary shares		28,834,303			22,806,812
Loss per ordinary share	$	(3.55	)	$	(4.81	)

Recently Adopted or Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which provides guidance to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the Company’s financial disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. The Company will adopt ASU 2023-09 for the 2025 year-end and is currently evaluating the potential impact of the adoption on the Company’s financial disclosures. ASU 2023-09 allows for adoption using either a prospective or retrospective transition method.

The Company has reviewed other Accounting Standards Updates recently issued by the FASB, and determined that none of these pronouncements will have a significant impact on the Company's consolidated financial statements and related disclosures.

Note 17 - Income Taxes - Reconciliation of Statutory Tax Rate to Effective Tax (Details) - USD ($)
$ in Thousands

12 Months Ended

24 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2023

Pretax loss

$ (98,324)

$ (108,028)

Statutory rate

23.00%

Income tax expense/(benefit) at statutory rate

$ (22,615)

$ (24,847)

Non-deductible expenses

5,704

1,052

R&D and orphan drug credits

(1,197)

(3,586)

Different tax rate of foreign subsidiaries

(689)

(263)

Uncertain tax positions

176

Change in valuation allowance(1)

^[1]

22,898

28,982

Other

(358)

241

Income tax expense

$ 3,920

$ 1,755

[1]	In the course of preparing the 2022 tax returns, adjustments were made for certain nondeductible amounts, reducing net operating loss carryforward and reflected as a change in valuation allowance of approximately $8.9 million in the current year.

Note 11 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Year one	$ 938	$ 1,146
Year two	825	904
Year three	58	788
Total future minimum lease payments	1,821	2,887
Less: Interest	(158)	(360)
Present value of lease liabilities	$ 1,663	2,527
Year four		$ 49

Note 12 - Revenue From Product Sales

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Text Block]

NOTE 12 – REVENUE FROM PRODUCT SALES

Net product sales consist of the following for the year ended December 31, 2023 and 2022 (in thousands):


	*Year Ended December 31, 2023*		*Year Ended December 31, 2022*
Jelmyto	$	82,713	$	64,357

Net revenue recognized includes gross revenue and management’s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340B drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company’s copay assistance program, and Medicare refunds for discarded drug, which are estimated based on the Company’s historical experience. Reserves related to items that are contractually able to be net settled are recognized as contra accounts receivable while other remaining reserves are recognized within other current liabilities on the consolidated balance sheets. The following table shows the activity with respect to sales reserves for the year ended December 31, 2023 and 2022, in thousands:

	*Reserves related to government sponsored programs*			*Other reserves*			*Total accrued sales reserves*
Balance as of December 31, 2021	$	373		$	941		$	1,314
Changes during 2022
Accruals		6,967			6,463			13,430
Utilizations		(6,750	)		(6,557	)		(13,307	)
Balance as of December 31, 2022	$	590		$	847		$	1,437
Changes during 2023
Accruals		11,110			12,258			23,368
Utilizations		(10,638	)		(8,196	)		(18,834	)
Balance as of December 31, 2023	$	1,062		$	4,909		$	5,971

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

Note 17 - Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Text Block]

NOTE 17 – INCOME TAXES

The Company is taxed under Israeli tax laws:

Corporate tax rate

The applicable Israeli tax rate relevant to the Company for 2022 and thereafter is 23%.

For financial reporting purposes, the expense for current income taxes consists of the following (in thousands):

	*2023*		*2022*
Current taxes:
U.S. Federal	$	2,937	$	584
U.S. State		983		1,171
Total current taxes	$	3,920	$	1,755

Deferred income taxes:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company and its subsidiary deferred tax assets are as follows (in thousands):

	*December 31,*
	*2023*			*2022*
In respect of:
Net operating loss carryforward	$	103,566		$	96,434
Research and development expenses		22,451			17,949
Stock-based compensation		11,953			11,485
Interest expense		1,345			-
In-process research and development		1,102			1,489
Right-of-use asset		(276	)		(434	)
Lease Liabilities		283			461
Accrued expenses		2,310			1,769
Depreciation of fixed assets		(45	)		(113	)
Other		875			561
Less—valuation allowance		(143,566	)		(129,601	)
Net deferred tax assets	$	—		$	—

The change in valuation allowance for the years ended December 31, 2023 and 2022 were as follows (in thousands):

	*2023*			*2022*
Balance at the beginning of the year	$	(129,601	)	$	(100,619	)
Changes during the year		(13,965	)		(28,982	)
Balance at the end of the year	$	(143,566	)	$	(129,601	)

The main reconciling items between the statutory tax rates of the Company and the effective rate are nondeductible expenses related to financing on the prepaid forward obligation and share-based compensation, the provision for a full valuation allowance in respect of tax benefits from carryforward tax losses due to the uncertainty of the realization of such tax benefits, utilization of tax credits and expense related to uncertain tax positions. A reconciliation of the Company’s statutory tax rate to effective tax is as follows (in thousands, except statutory rate):

	*December 31,*
	*2023*			*2022*
Pretax loss	$	(98,324	)	$	(108,028	)
Statutory rate		23	%		23	%
Income tax expense/(benefit) at statutory rate		(22,615	)		(24,847	)
Additional tax (tax saving) in respect of:
Non-deductible expenses		5,704			1,052
R&D and orphan drug credits		(1,197	)		(3,586	)
Different tax rate of foreign subsidiaries		(689	)		(263	)
Uncertain tax positions		176			176
Change in valuation allowance⁽¹⁾		22,898			28,982
Other		(358	)		241
Income tax expense	$	3,920		$	1,755

⁽¹⁾In the course of preparing the 2022 tax returns, adjustments were made for certain nondeductible amounts, reducing net operating loss carryforward and reflected as a change in valuation allowance of approximately $8.9 million in the current year.

Pretax loss for December 31, 2023 and 2022 includes pretax loss from foreign (United States) jurisdictions of $17.9 million and $13.3 million, respectively.

The Internal Revenue Code contains provisions that may limit our use of federal net operating loss carryforwards if significant changes occur in the constructive stock ownership of UroGen Pharma Inc. In the event it has had an “ownership change” within the meaning of Section 382 of the Code, utilization of its net operating loss carryforwards could be restricted under Section 382 of the Code and similar state provisions. Such limitations could result in the expiration of the net operating carryforwards incurred before 2018 before their utilization.

Losses for tax purposes carried forward to future years

As of December 31, 2023 and 2022, the Company had approximately $452.0 million and $419.1 million of carryforward tax losses, prior to tax effecting, respectively, available to reduce future taxable income without limitation of use.

Uncertain tax positions

A reconciliation of the beginning and ending amount of uncertain tax positions is as follows (in thousands):

	*2023*		*2022*
Uncertain tax positions at the beginning of the year	$	3,018	$	2,842
Gross increases — tax positions in current period		—		—
Gross increases — tax positions in prior period		176		176
Uncertain tax positions at the end of the year	$	3,194	$	3,018

The balances of uncertain tax positions as of December 31, 2023 would affect the Company’s effective tax rate if recognized.

The Company has recorded a liability for uncertain tax positions of $3.2 million as of December 31, 2023 for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of December 31, 2023, the Company's liability for uncertain tax positions includes $1.2 million of accrued interest and penalties.

The Company operates on a global basis and is subject to tax laws and regulations in the United States and Israel. The estimate of the Company’s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities.

The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and has recorded the gross uncertain tax positions as a long-term liability.

The Company has received final tax assessments up to and including its 2017 tax year.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 6,514	$ 5,527
Accrued sales reserves	4,391	618
Accrued clinical expenses	1,246	2,853
Accrued research and development expenses	1,049	1,285
Accrued selling, general and administrative expenses	2,752	1,609
Accrued other expenses	586	491
Total accounts payable and accrued expenses	$ 16,538	$ 12,383

Note 11 - Leases - Amounts of Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Right-of-use assets	$ 1,671	$ 2,452
Long-term lease liabilities	844	1,586
Other Current Liabilities [Member]
Other current liabilities	$ 819	$ 941

Note 9 - Prepaid Forward Obligation

12 Months Ended

Dec. 31, 2023

Prepaid Forward Obligation Disclosure [Text Block]

NOTE 9 – Prepaid Forward Obligation

In March 2021, the Company entered into a prepaid forward agreement with RTW Investments (“RTW”). Under the terms of the RTW Transaction, the Company received $75.0 million ($72.4 million net of transaction costs) to support the continued launch of Jelmyto and the development of UGN-102. In return for the transferred funds, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto in an amount equal to: (i) 9.5% of annual net sales up to $200 million, (ii) 3.0% of annual net sales for annual net sales between $200 million and $300 million, and (iii) 1.0% of annual net sales for annual net sales above $300 million. If certain revenue thresholds for Jelmyto aggregate worldwide annual net sales are not met, the future cash payments to RTW with respect to Jelmyto annual net sales up to $200 million will increase by 3.5%, and may decrease back to 9.5% dependent on the Company meeting certain subsequent Jelmyto aggregate worldwide annual net sales thresholds. The rate in effect for the year ended December 31, 2023 for annual net sales up to $200 million was 13.0%.

In addition, subject to FDA approval of UGN-102, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of UGN-102 in an amount equal to: (i) 2.5% of annual net sales up to $200 million, (ii) 1.0% of annual net sales for annual net sales between $200 million and $300 million, and (iii) 0.5% of annual net sales for annual net sales above $300 million. If the Company does not receive FDA approval for UGN-102 by a specified date, the future cash payments to RTW with respect to aggregate worldwide annual net sales of Jelmyto across all Jelmyto annual net sales tiers will increase by 1.5%.

In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than $300 million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a first priority security interest in Jelmyto and UGN-102, including the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to these products.

In May 2021, following the receipt of necessary regulatory approvals, the Company received the $75.0 million prepaid forward payment ($72.4 million net of transaction costs) from RTW and recognized an associated prepaid forward obligation liability. Each period the Company makes a payment to RTW, an expense is recognized related to financing on the prepaid forward obligation based on an imputed rate derived from the expected future payments. Management reassesses the effective rate each period based on the current carrying value of the obligation and the revised estimated future payments. Changes in future payments from previous estimates are included in future financing expense. The Company does not expect to make any principal payments in the next 12 months.

The following table shows the activity with respect to the carrying value of the prepaid forward liability for the year ended December 31, 2023 and 2022 (in thousands):

Carrying value of prepaid forward obligation as of December 31, 2021	$	85,713
Financing on prepaid forward obligation		21,559
Amounts paid and payable⁽¹⁾		(8,349	)
Carrying value of prepaid forward obligation as of December 31, 2022		98,923
Financing on prepaid forward obligation		21,552
Amounts paid and payable⁽¹⁾		(10,753	)
Carrying value of prepaid forward obligation as of December 31, 2023	$	109,722

⁽¹⁾$3.0 million and $2.3 million of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the consolidated balance sheets as of December 31, 2023 and December 31, 2022, respectively.

Note 17 - Income Taxes (Details Textual) - USD ($)
$ in Thousands

12 Months Ended

24 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2023

Dec. 31, 2021

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent

23.00%

Income (Loss) from Continuing Operations before Income Taxes, Foreign

$ (17,900)

$ (13,300)

Operating Loss Carryforwards

452,000

419,100

$ 452,000

Unrecognized Tax Benefits

3,194

3,018

3,194

$ 2,842

Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued

1,200

$ 1,200

Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

^[1]

22,898

$ 28,982

SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]

Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

$ 8,900

[1]	In the course of preparing the 2022 tax returns, adjustments were made for certain nondeductible amounts, reducing net operating loss carryforward and reflected as a change in valuation allowance of approximately $8.9 million in the current year.

Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Financing on prepaid forward obligation

$ 21,552

$ 21,559

Amounts paid and payable (1)

^[1]

(10,753)

(8,349)

Carrying value of prepaid forward obligation as of December 31, 2021

$ 109,722

$ 98,923

[1]	$3.0 million and $2.3 million of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the consolidated balance sheets as of December 31, 2023 and December 31, 2022, respectively.

Note 15 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Dec. 20, 2023	Jul. 26, 2023	Dec. 31, 2023	Dec. 31, 2022
Common Stock, Shares Authorized (in shares)			100,000,000	100,000,000
Common Stock, Shares, Outstanding, Ending Balance (in shares)			32,490,119	23,129,953
Proceeds from Issuance of Private Placement		$ 120.0
Conversion of Prefunded Warrants Into Ordinary Shares [Member]
Conversion of Stock, Shares Issued (in shares)	1,599,733
Conversion of Stock, Shares Converted (in shares)	1,599,840
Pre-funded Warrant [Member]
Class of Warrant or Right, Outstanding (in shares)		5,278,776
Class of Warrants or Rights, Issuance Price Per Share (in dollars per share)		$ 9.539
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.001
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		7,300,380
Shares Issued, Price Per Share (in dollars per share)		$ 9.54
Placement Agents and Financial Advisors Fees		$ 3.6
Private Placement [Member] \| Monograph Capital Partners [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,572,327
Proceeds from Issuance of Private Placement		$ 15.0

Note 17 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net operating loss carryforward	$ 103,566	$ 96,434
Research and development expenses	22,451	17,949
Stock-based compensation	11,953	11,485
Interest expense	1,345	0
In-process research and development	1,102	1,489
Right-of-use asset	(276)	(434)
Lease Liabilities	283	461
Accrued expenses	2,310	1,769
Depreciation of fixed assets	(45)	(113)
Other	875	561
Less—valuation allowance	(143,566)	(129,601)	$ (100,619)
Net deferred tax assets	$ 0	$ 0

Note 9 - Prepaid Forward Obligation (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Activity in the Carrying Value of the Prepaid Forward Liability [Table Text Block]

Carrying value of prepaid forward obligation as of December 31, 2021	$	85,713
Financing on prepaid forward obligation		21,559
Amounts paid and payable⁽¹⁾		(8,349	)
Carrying value of prepaid forward obligation as of December 31, 2022		98,923
Financing on prepaid forward obligation		21,552
Amounts paid and payable⁽¹⁾		(10,753	)
Carrying value of prepaid forward obligation as of December 31, 2023	$	109,722

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property and equipment, gross	$ 4,641	$ 4,447
Less: accumulated depreciation and amortization	(3,952)	(3,150)
Property and equipment, net	689	1,297
Laboratory Equipment [Member]
Property and equipment, gross	464	452
Computers and Software [Member]
Property and equipment, gross	2,293	2,168
Furniture [Member[
Property and equipment, gross	612	602
Leasehold Improvements [Member]
Property and equipment, gross	617	617
Manufacturing Equipment [Member]
Property and equipment, gross	$ 655	$ 608

Note 16 - Share-based Compensation

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Text Block]

NOTE 16 – SHARE-BASED COMPENSATION

In October 2010, the Board approved a share option plan (the “2010 Plan”) for grants to Company employees, consultants, directors, and other service providers. Subsequently, in March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan" and, together with the 2010 Plan, the "Plans"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants.

The grant of options to Israeli employees under the Plans is subject to the terms stipulated by Section 102 of the Israeli Income Tax Ordinance (“Section 102”). The option grants are subject to the track chosen by the Company, either the “regular income” track or the “capital gains” track, as set out in Section 102. The Company registered the Plans under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section 102, the Company is not allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plans, including amounts recorded as salary benefits in the Company’s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plans is subject to Section 3(i) of the Israeli Income Tax Ordinance.

Employees are typically granted stock options and/or restricted stock units ("RSUs"), upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of stock options upon initial appointment to the Board, and/or stock options annually. The term of any option granted under the Plans cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company’s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share on the date of grant.

The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date.

The expected volatility is based on a mix of the Company’s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees’ exercise behavior, and for non-employees, and directors using the contractual term.

On January 31, 2023, the Board approved a performance stock unit ("PSU") award of 100,000 shares under the 2017 Plan to the Company's Chief Executive Officer, subject to shareholder approval. Vesting of these PSUs will depend upon obtaining regulatory approval for the Company’s lead product candidate UGN-102 in the three years following the grant. The PSU award was approved by the Company’s shareholders at the 2023 Annual Shareholders’ Meeting on September 7, 2023.

The maximum number of ordinary shares that was initially authorized for issuance under the 2017 Plan was 1,400,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167 shares. On October 12, 2018, the Company increased the number of ordinary shares authorized for issuance under the 2017 Plan by 1,900,000 to 3,550,167 shares. On June 8, 2020, the Company’s shareholders approved an increase to the number of ordinary shares authorized for issuance under the 2017 Plan by 400,000 to 3,950,167 shares. On June 7, 2021, the Company’s shareholders approved an increase to the number of ordinary shares authorized for issuance under the 2017 Plan by 400,000 to 4,350,167 shares. On June 8, 2022, the Company's shareholders approved an increase to the number of ordinary shares authorized for issuance under the 2017 Plan by 400,000 to 4,750,167 shares. On September 7, 2023, the Company's shareholders approved an increase to the number of ordinary shares authorized for issuance under the 2017 Plan by 450,000 to 5,200,167 shares.

In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the “Inducement Plan”). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to inducement awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company. In December 2021, the Board approved a 300,000 increase in the share reserve of the Inducement Plan to 1,200,000 shares.

As of December 31, 2023, 3,784,480 ordinary shares are subject to outstanding awards under the Company's share-based compensation plans, and 1,009,614 ordinary shares remain available for future awards.

Options granted:

Set forth below are grants made by the Company as of December 31, 2023. The majority of options vest over three years and expire on the tenth anniversary of the date of grant.

During 2023, the Company granted 530,000 options with exercise prices ranging from $8.84 to $17.94 per share.

During 2022, the Company granted 410,064 options with exercise prices ranging from $5.19 to $11.88 per share.

The fair value of options granted during 2023 and 2022 was $4.3 million and $2.2 million, respectively.

The total unrecognized compensation cost of options as of December 31, 2023 was $4.4 million, which is expected to be recognized over a weighted average period of 1.7 years.

The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:

	*2023*		*2022*
Value of ordinary shares		8.84417.944		5.19911.888
Dividend yield		0%		0%
Expected volatility		67.21%-81.00%		72.35%-81.00%
Risk-free interest rate		3.47%-4.42%		1.69%-4.14%
Expected term (in years)		6.0-10 years		6.0-10 years

The expected volatility is based on a mix of the Company's historical volatility and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees’ exercise behavior, and for non-employees, and directors using the contractual term.

The following table summarizes the number of employee and non-employee options outstanding under the Plan for the years ended December 31, 2023 and 2022, and related information:

	*Number of options*			*Weighted Average price per share*
Outstanding as of December 31, 2021		2,969,557		$	27.70
Granted		410,064			7.82
Forfeited		(496,417	)		27.97
Exercised		(292,665	)		5.16
Outstanding as of December 31, 2022		2,590,539		$	27.05
Granted		530,000			11.75
Forfeited		(268,316	)		27.42
Exercised		(166,427	)		5.25
Outstanding as of December 31, 2023		2,685,796		$	25.35
Vested and expected to vest, December 31, 2023		2,685,796		$	25.35
Exercisable, December 31, 2023		1,831,743		$	6.10

The intrinsic value of stock options exercised was $0.7 million and $0.8 million for the years ended December 31, 2023 and 2022, respectively.

The following table summarizes the outstanding and exercisable options as of December 31, 2023:

		*Options outstanding*				*Options exercisable*
*Exercise price per share*		*Number of options outstanding at end of year*		*Weighted average remaining contractual life*		*Number of options exercisable at end of year*		*Weighted average remaining contractual life*
$	0.00 - 10.00		386,064		13.00		152,018		12.22
$	10.01 - 20.00		920,000		8.27		372,496		7.11
$	20.01 - 30.00		455,300		6.11		382,797		5.92
$	30.01 - 40.00		201,000		4.83		201,000		4.83
$	40.01 - 50.00		637,432		4.78		637,432		4.78
$	50.01 - 59.23		86,000		4.43		86,000		4.43
			2,685,796				1,831,743

The aggregate intrinsic value of the total vested and exercisable options as of December 31, 2023 is $1.6 million.

The following table summarizes information about RSU activity as of December 31, 2023:

	*Outstanding Restricted Stock Units*
Outstanding as of December 31, 2021		753,274
Granted		445,980
Vested and released		(374,293	)
Forfeited		(134,006	)
Outstanding as of December 31, 2022		690,955
Granted		854,249
Vested and released		(293,626	)
Forfeited		(152,894	)
Outstanding as of December 31, 2023		1,098,684

The fair value of RSUs granted during 2023 and 2022 was $10.4 million and $3.2 million, respectively. The total unrecognized compensation cost of RSUs as of December 31, 2023 is $9.2 million with a weighted average recognition period of 1.86 years.

The following table illustrates the effect of share-based compensation on the Statements of Operations:

	*Year ended December 31,*
	*2023*		*2022*
Research and development expenses	$	1,905	$	2,626
Selling, general and administrative expenses		7,439		7,954
Total share-based compensation expense	$	9,343	$	10,580

Consolidated Balance Sheets (Parentheticals) - ₪ / shares	Dec. 31, 2023	Dec. 31, 2022
Ordinary shares, par value (in ILS per share)	₪ 0.01	₪ 0.01
Ordinary shares, authorized (in shares)	100,000,000	100,000,000
Ordinary shares, issued (in shares)	32,490,119	23,129,953
Ordinary shares, outstanding (in shares)	32,490,119	23,129,953

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2023	Mar. 07, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001668243
Entity Registrant Name	UroGen Pharma Ltd.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	IL
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Trading Symbol	URGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 190,400,000
Entity Common Stock, Shares Outstanding		34,122,087
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Florham Park, New Jersey

Note 11 - Leases (Tables)

12 Months Ended

Dec. 31, 2023

Lease, Cost [Table Text Block]

	*Year Ended December 31, 2023*			*Year Ended December 31, 2022*
Operating lease cost	$	934		$	975
Sublease income		(224	)		(224	)
Variable lease cost		73			65
	$	783		$	816

Assets and Liabilities, Lessee [Table Text Block]

	*Year Ended December 31, 2023*		*Year Ended December 31, 2022*
Right-of-use assets	$	1,671	$	2,452
Long-term lease liabilities		844		1,586
Other current liabilities		819		941

Schedule of Supplemental Information Related to Leases [Table Text Block]

	*Year Ended December 31, 2023*			*Year Ended December 31, 2022*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		1,169			1,195
Right-of-use assets obtained in exchange for new operating lease liabilities		122			2,165
Weighted-average remaining lease term of operating leases (in years)		1.92			2.73
Weighted-average discount rate of operating leases		10.21	%		10.25	%

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

	*Operating Leases*
Years ending December 31,
2024	$	938
2025		825
2026		58
Total future minimum lease payments	$	1,821
Less: Interest		(158	)
Present value of lease liabilities	$	1,663

	*Operating Leases*
Years ending December 31,
2023	$	1,146
2024		904
2025		788
2026		49
Total future minimum lease payments	$	2,887
Less: Interest		(360	)
Present value of lease liabilities	$	2,527

Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]

	*Operating Leases*
Years ending December 31,
2024	$	49
Total future minimum sublease payments	$	49

	*Operating Leases*
Years ending December 31,
2023	$	251
2024		49
Total future minimum sublease payments	$	300

Note 20 - Subsequent Events (Details Textual) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Mar. 13, 2024	Feb. 29, 2024	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Issuance of Common Stock			$ 67,358	$ 0
Subsequent Event [Member] \| Secured Debt [Member]
Secured Long Term Debt, Third Tranche	$ 25,000
Secured Long Term Debt, Fourth Tranche	$ 75,000
Subsequent Event [Member] \| Secured Debt [Member] \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	7.25%
Subsequent Event [Member] \| Secured Debt [Member] \| Additional Adjustment on SOFR Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.26161%
Subsequent Event [Member] \| ATM Sales Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,400,468
Proceeds from Issuance of Common Stock		$ 26,600
Net Proceeds From Issuance of Common Stock, After Deducting Sales Commissions		25,900
Sale of Stock, Remaining Amount Authorized		$ 56,800

Note 6 - Fair Value Measurements

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Text Block]

NOTE 6 – FAIR VALUE MEASUREMENTS

The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The carrying amounts of the Company’s cash, restricted cash, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these assets and liabilities.

The carrying value of the prepaid forward obligation (See Note 9 - Prepaid Forward Obligation) approximates its fair value. The Company estimated the fair value of the prepaid forward obligation using Level 3 inputs, including internally developed financial forecasts and management's estimate of probability of success related to product candidates, and determined that the effective interest rate in the obligation approximates market rates for loans with similar terms and risk characteristics.

The Company estimated the fair value of long-term debt (see Note 10 - Long-Term Debt) using the income approach with Level 3 inputs. The Company estimated future floating rate interest payments using a forward curve of a three-month benchmark rate, and estimated fair value based on publicly available data reported in the financial statements of publicly traded venture lending companies. Based on a reasonable range of yields for debt instruments of similar tenor in a similar industry, the Company determined that the carrying value of the long-term debt on the Company's balance sheet approximates its fair value.

No transfers between levels have occurred during the periods presented.

Assets measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2023 are as follows (in thousands):

			*Fair Value Measurements Using*
			*Quoted Prices*		*Significant*
			*in Active*		*Other*
	*Balance as of*		*Markets for*		*Observable*
	*December 31,*		*Identical Assets*		*Inputs*
	*2023*		*(Level 1)*		*(Level 2)*
Assets:
Cash equivalents
Money market funds	$	9,704	$	9,704	$	—
Marketable securities
U.S. government	$	28,634	$	28,634	$	—
Corporate bonds		6,738		—		6,738
Commercial paper		7,101		—		7,101
Certificates of deposit		3,995		—		3,995
Total marketable securities	$	46,468	$	28,634	$	17,834
Total assets at fair value	$	56,172	$	38,338	$	17,834

Assets measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2022 are as follows (in thousands):

			*Fair Value Measurements Using*
			*Quoted Prices*		*Significant*
			*in Active*		*Other*
	*Balance as of*		*Markets for*		*Observable*
	*December 31,*		*Identical Assets*		*Inputs*
	*2022*		*(Level 1)*		*(Level 2)*
Marketable securities
U.S. government	$	28,693	$	28,693	$	—
Corporate bonds		2,387		—		2,387
Commercial paper		9,392		—		9,392
Certificates of deposit		4,084		—		4,084
Total marketable securities	$	44,556	$	28,693	$	15,863

The Company’s investments in U.S. government bonds and money market funds are measured based on publicly available quoted market prices for identical securities as of December 31, 2023 and 2022. The Company's investments in corporate bonds, commercial paper and certificates of deposits are measured based on quotes from market makers for similar items in active markets.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Maturities within one year	$ 51,670	$ 44,556
Maturities after one year through three years	4,502	0
Total investments	$ 56,172	$ 44,556

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2023 shares
ecd_TradingArrByIndTable
Material Terms of Trading Arrangement [Text Block]	*Item 9B.* Other Information** Trading Plans On December 26, 2023, our Chief Medical Officer, Mark Schoenberg, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, to sell up to 30,000 ordinary shares. The trading plan expires on April 10, 2025. Amended and Restated Loan Agreement On March 13, 2024, we entered into an amended and restated loan agreement with Pharmakon for an additional third and fourth tranche of senior secured loan. The third tranche of $25.0 million is mandatory and required to be drawn by September 30, 2024, subject to satisfaction of customary conditions. The fourth tranche of $75.0 million may be drawn at our option no later than August 29, 2025, subject to (i) having successfully drawn the immediately preceding $25.0M tranche, (ii) receiving FDA approval of an NDA for UGN-102 no later than June 30, 2025 and (iii) satisfaction of customary conditions. All outstanding loans with Pharmakon accrue interest using a benchmark rate of 3-month SOFR plus 7.25% plus an additional adjustment of 0.26161%. All outstanding principal will be required to be repaid in four equal quarterly installments commencing in the second quarter of 2026, with a one-year extension upon FDA approval of an NDA for UGN-102. All outstanding loans with Pharmakon can be prepaid in whole at the Company's discretion, at any time, subject to prepayment premiums, make-whole amounts and fees. Notice of 2024* Annual Meeting Date and Related Deadlines* As of the date of this Annual Report, we intend to hold our 2024 Annual meeting of Shareholders (the "2024 Annual Meeting of Shareholders") on or about August 7, 2024. This date is more than 30 days before the one-year anniversary of our 2023 annual meeting of shareholders, which was held on September 7, 2023. Under Section 66(b) of the Israeli Companies Law, 5759-1999, as amended from time to time, and the regulations promulgated thereunder (collectively, the “Companies Law”), shareholders who hold, in the aggregate, at least 1% of the voting power in the Company may submit a request to include an item to the agenda within seven days following the Company’s notice of convening a shareholders’ general meeting at which directors are to be elected and certain other proposals are to be considered (or within three days of the Company’s notice in other instances), provided the requested item is appropriate for presentation at a general meeting and for consideration by the shareholders. In addition to the eligibility requirements under the Companies Law, our articles of association specify additional procedural requirements for shareholder proposals. Under our articles of association, in the event that the date of the annual general meeting is advanced more than 30 days prior to the anniversary of the preceding year’s annual general meeting, notice by the proposing shareholder, in order to be timely, must be received no earlier than the close of business 120 days prior to such annual general meeting, April 9, 2024, and no later than the close of business 90 days prior to such annual general meeting, May 9, 2024. In addition, shareholder proposals may be submitted for inclusion in a proxy statement under Rule 14a-8 under the Exchange Act. Under Rule 14a-8 of the Exchange Act, to be eligible for inclusion in our proxy materials for the 2024 Annual Meeting of Shareholders, shareholder proposals must be received by us a reasonable time before we begin to print and send our proxy materials. We have determined that April 13, 2024, which is the date disclosed in our definitive proxy statement on Schedule 14A for our 2023 annual meeting of shareholders, remains a reasonable time before we expect to begin to print and distribute our proxy materials for our 2024 Annual Meeting, and that any shareholder proposals must be received on or before the close of business on that day. In addition, Rule 14a-8 proposals must otherwise comply with the requirements of the rule. Additional requirements regarding shareholder proposals submitted for inclusion in our proxy materials for an annual general meeting of shareholders can be found in the articles of association, which is available as an exhibit to this Annual Report. Proposals should be addressed to: UroGen Pharma Ltd., 400 Alexander Park Drive, 4^th Floor, Princeton, New Jersey 08540. In addition to satisfying the foregoing requirements under our articles of association, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than our board of directors’ nominees must provide notice that sets forth any additional information required by Rule 14a-19 promulgated under the Exchange Act.
Mark Schoenberg [Member]
ecd_TradingArrByIndTable
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Adoption Date	December 26, 2023
Trading Arrangement, Individual Title	Chief Medical Officer
Trading Arrangement, Individual Name	Mark Schoenberg
Rule 10b5-1 Arrangement Adopted [Flag]	true
Trading Arrangement, Securities Aggregate Available Amount	30,000
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Note 17 - Income Taxes - Reconciliation of Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Uncertain tax positions at the beginning of the year	$ 3,018	$ 2,842
Gross increases — tax positions in current period	0	0
Gross increases — tax positions in prior period	176	176
Uncertain tax positions at the end of the year	$ 3,194	$ 3,018

Consolidated Statements of Cash Flow (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Issuance costs	$ (0)
Private Placement [Member]
Issuance costs	2,288
Private Placement [Member] \| Pre-funded Warrant [Member]
Issuance costs	$ 1,654

Note 5 - Inventories

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Text Block]

NOTE 5 – INVENTORIES

Inventories consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands):

	*December 31, 2023*		*December 31, 2022*
Raw materials ⁽¹⁾	$	4,464	$	4,676
Finished goods		2,877		2,019
Total inventories	$	7,341	$	6,695

⁽¹⁾ $1.7 million and $2.4 million of raw materials are included within other non-current assets on the consolidated balance sheets at December 31, 2023 and December 31, 2022, respectively. Changes in non-current assets are reflected on the consolidated statements of cash flows within the caption of other non-current assets.

Note 20 - Subsequent Events

12 Months Ended

Dec. 31, 2023

Subsequent Events [Text Block]

NOTE 20 – SUBSEQUENT EVENTS

In February 2024, the Company sold 1,400,468 ordinary shares under the ATM Sales Agreement, for gross proceeds of approximately $26.6 million. The net proceeds to the Company after deducting sales commissions to Cowen were approximately $25.9 million. Following such sale, the remaining capacity under the ATM Sales Agreement is approximately $56.8 million.

On March 13, 2024, we entered into an amended and restated loan agreement with Pharmakon for an additional third and fourth tranche of senior secured loan. The third tranche of $25.0 million is mandatory and required to be drawn by September 30, 2024, subject to satisfaction of customary conditions. The fourth tranche of $75.0 million may be drawn at our option no later than August 29, 2025, subject to (i) having successfully drawn the immediately preceding $25.0M tranche, (ii) receiving FDA approval of an NDA for UGN-102 no later than June 30, 2025 and (iii) satisfaction of customary conditions.

All outstanding loans with Pharmakon accrue interest using a benchmark rate of 3-month SOFR plus 7.25% plus an additional adjustment of 0.26161%. All outstanding principal will be required to be repaid in four equal quarterly installments commencing in the second quarter of 2026, with a one-year extension upon FDA approval of an NDA for UGN-102. All outstanding loans with Pharmakon can be prepaid in whole at the Company's discretion, at any time, subject to prepayment premiums, make-whole amounts and fees.

Note 16 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions								1 Months Ended	12 Months Ended
	Dec. 31, 2023	Sep. 07, 2023	Jun. 08, 2022	Jun. 07, 2021	Jun. 08, 2020	Oct. 12, 2018	Jan. 01, 2018	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2023	May 31, 2019	Mar. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	3,784,480								3,784,480
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	1,009,614								1,009,614
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)									530,000	410,064
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)									$ 8.84	$ 5.19
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)									$ 17.94	$ 11.88
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Fair Value									$ 4.3	$ 2.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 4.4								$ 4.4
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									1 year 8 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value									$ 0.7	0.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 1.6								$ 1.6
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Payment Arrangement, Option [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									1 year 10 months 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Granted, Fair Value									$ 10.4	$ 3.2
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 9.2								$ 9.2
Restricted Stock Units (RSUs) [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.00%
Share Option Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
Share-based Compensation Arrangement By Share-based Payment Award, Individual Voting Powers, Percentage	10.00%
Two Thousand Seventeen Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		5,200,167	4,750,167	4,350,167	3,950,167	3,550,167	1,650,167						1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		450,000	400,000	400,000	400,000	1,900,000	250,167
Two Thousand Seventeen Equity Incentive Plan [Member] \| Performance Shares [Member] \| Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)											100,000
The 2019 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)								1,200,000				900,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)								300,000
Maximum [Member] \| Share Option Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Minimum [Member] \| Share Option Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	100.00%
Share-based Compensation Arrangement By Share-based Payment Award, Percentage of Purchase Price for Individuals Having More than Ten Percent of Combined Voting Power	110.00%

Note 11 - Leases - Supplemental Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating cash flows from operating leases	$ 1,169	$ 1,195
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 122	$ 2,165
Weighted-average remaining lease term of operating leases (Year)	1 year 11 months 1 day	2 years 8 months 23 days
Weighted-average discount rate of operating leases	10.21%	10.25%

Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Interest income	$ 2,641	$ 938
Other income, net	838	72
Total interest and other income, net	$ 3,479	$ 1,010

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Functional Currency

Cash, Cash Equivalents and Marketable Securities Policy [Policy Text Block]

Cash and Cash Equivalents; Marketable Securities

Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Income Tax, Policy [Policy Text Block]

Income Taxes

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are depreciated over the following useful lives (in years):

	*Useful Lives*
Computers and software		3
Laboratory equipment		3 - 6.5
Furniture		5 - 16.5
Manufacturing equipment		2 - 10

Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.

Prepaid Forward Obligation Policy [Policy Text Block]

Prepaid Forward Obligation

Debt, Policy [Policy Text Block]

Long-Term Debt

Lessee, Leases [Policy Text Block]

Leases

The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.

Revenue [Policy Text Block]

Revenue

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Selling, General and Administrative Expenses, Policy [Policy Text Block]

Selling, General and Administrative Expenses

Share-Based Payment Arrangement, Director [Policy Text Block]

Share-Based Compensation

Stockholders' Equity, Policy [Policy Text Block]

Pre-funded Warrants

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Ordinary Share

For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.

The following table summarizes the calculation of basic and diluted loss per ordinary share for the periods presented (in thousands, except share and per share amounts):

	*Year Ended December 31,*
	*2023*			*2022*
Basic and diluted:
Loss attributable to equity holders of the Company	$	(102,244	)	$	(109,783	)
Weighted-average number of ordinary shares		28,834,303			22,806,812
Loss per ordinary share	$	(3.55	)	$	(4.81	)

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted or Issued Accounting Pronouncements

Note 13 - License and Collaboration Agreements

12 Months Ended

Dec. 31, 2023

Collaborative Arrangement Disclosure [Text Block]

NOTE 13 – LICENSE AND COLLABORATION AGREEMENTS

Agenus Agreement

In November 2019, the Company entered into a license agreement with Agenus Inc. (“Agenus”), pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus’s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as AGEN1884 (zalifrelimab), an anti-CTLA-4 antagonist, for the treatment of cancers of the urinary tract via intravesical delivery. UGN-301 is a formulation of zalifrelimab administered using RTGel technology that is in Phase 1 clinical development for high-grade NMIBC.

MD Anderson Agreement

In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 as an investigational treatment for high-grade NMIBC. Pursuant to the agreement, the Company has made bi-annual payments totaling $2.0 million to MD Anderson to fund the collaboration, recognized evenly over the associated period through research and development expenses. In July 2022, the Company determined that it had achieved the objectives that it established when the agreement was initiated, and notified MD Anderson that it was exercising its right to conclude the collaboration in 2022 as the Company did not foresee initiating further development activities as part of the collaboration, although the Company will continue to collaborate on existing joint projects. As a result of this notification, the Company is not responsible for any further fixed bi-annual funding payments in 2023, although the Company will be responsible for costs related to existing joint projects to the extent they exceed the payments already made to MD Anderson.

Note 5 - Inventories (Details Textual) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Inventory, Raw Materials, Net of Reserves

^[1]

$ 4,464

$ 4,676

Other Noncurrent Assets [Member]

Inventory, Raw Materials, Net of Reserves

$ 1,700

$ 2,400

[1]

$1.7 million and $2.4 million of raw materials are included within other non-current assets on the consolidated balance sheets at December 31, 2023 and December 31, 2022, respectively. Changes in non-current assets are reflected on the consolidated statements of cash flows within the caption of other non-current assets.

Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair value	$ 46,468	$ 44,556
Money Market Funds [Member]
Cash equivalents, fair value	9,704
US Treasury Securities [Member]
Fair value	28,634
Corporate Debt Securities [Member]
Fair value	6,738	2,387
Certificates of Deposit [Member]
Fair value	3,995	4,084
Fair Value, Recurring [Member]
Fair value	46,468	44,556
Total assets at fair value	56,172
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	28,634	28,693
Total assets at fair value	38,338
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	17,834	15,863
Total assets at fair value	17,834
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Cash equivalents, fair value	9,704
Fair Value, Recurring [Member] \| Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents, fair value	9,704
Fair Value, Recurring [Member] \| Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents, fair value	0
Fair Value, Recurring [Member] \| Commercial Paper [Member]
Cash equivalents, fair value	7,101
Fair Value, Recurring [Member] \| Commercial Paper [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents, fair value	0
Fair Value, Recurring [Member] \| Commercial Paper [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents, fair value	7,101
Fair Value, Recurring [Member] \| US Treasury Securities [Member]
Fair value	28,634	28,693
Fair Value, Recurring [Member] \| US Treasury Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	28,634	28,693
Fair Value, Recurring [Member] \| US Treasury Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	0	0
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member]
Fair value	6,738	2,387
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	0	0
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	6,738	2,387
Fair Value, Recurring [Member] \| Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Fair value		9,392
Fair Value, Recurring [Member] \| Commercial Paper, Not Included with Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value		0
Fair Value, Recurring [Member] \| Commercial Paper, Not Included with Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value		9,392
Fair Value, Recurring [Member] \| Certificates of Deposit [Member]
Fair value	3,995	4,084
Fair Value, Recurring [Member] \| Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	0	0
Fair Value, Recurring [Member] \| Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	$ 3,995	$ 4,084

Note 3 - Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment, Useful Life [Table Text Block]

	*Useful Lives*
Computers and software		3
Laboratory equipment		3 - 6.5
Furniture		5 - 16.5
Manufacturing equipment		2 - 10

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	*Year Ended December 31,*
	*2023*			*2022*
Basic and diluted:
Loss attributable to equity holders of the Company	$	(102,244	)	$	(109,783	)
Weighted-average number of ordinary shares		28,834,303			22,806,812
Loss per ordinary share	$	(3.55	)	$	(4.81	)

Note 17 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	*2023*		*2022*
Current taxes:
U.S. Federal	$	2,937	$	584
U.S. State		983		1,171
Total current taxes	$	3,920	$	1,755

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	*December 31,*
	*2023*			*2022*
In respect of:
Net operating loss carryforward	$	103,566		$	96,434
Research and development expenses		22,451			17,949
Stock-based compensation		11,953			11,485
Interest expense		1,345			-
In-process research and development		1,102			1,489
Right-of-use asset		(276	)		(434	)
Lease Liabilities		283			461
Accrued expenses		2,310			1,769
Depreciation of fixed assets		(45	)		(113	)
Other		875			561
Less—valuation allowance		(143,566	)		(129,601	)
Net deferred tax assets	$	—		$	—

Summary of Valuation Allowance [Table Text Block]

	*2023*			*2022*
Balance at the beginning of the year	$	(129,601	)	$	(100,619	)
Changes during the year		(13,965	)		(28,982	)
Balance at the end of the year	$	(143,566	)	$	(129,601	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*December 31,*
	*2023*			*2022*
Pretax loss	$	(98,324	)	$	(108,028	)
Statutory rate		23	%		23	%
Income tax expense/(benefit) at statutory rate		(22,615	)		(24,847	)
Additional tax (tax saving) in respect of:
Non-deductible expenses		5,704			1,052
R&D and orphan drug credits		(1,197	)		(3,586	)
Different tax rate of foreign subsidiaries		(689	)		(263	)
Uncertain tax positions		176			176
Change in valuation allowance⁽¹⁾		22,898			28,982
Other		(358	)		241
Income tax expense	$	3,920		$	1,755

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	*2023*		*2022*
Uncertain tax positions at the beginning of the year	$	3,018	$	2,842
Gross increases — tax positions in current period		—		—
Gross increases — tax positions in prior period		176		176
Uncertain tax positions at the end of the year	$	3,194	$	3,018

Note 4 - Other Financial Information (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	*December 31, 2023*		*December 31, 2022*
Accounts payable	$	6,514	$	5,527
Accrued sales reserves		4,391		618
Accrued clinical expenses		1,246		2,853
Accrued research and development expenses		1,049		1,285
Accrued selling, general and administrative expenses		2,752		1,609
Accrued other expenses		586		491
Total accounts payable and accrued expenses	$	16,538	$	12,383

Interest Income and Interest Expense Disclosure [Table Text Block]

	*Year Ended December 31,*
	*2023*		*2022*
Interest income	$	2,641	$	938
Other income, net		838		72
Total interest and other income, net	$	3,479	$	1,010

Note 5 - Inventories - Inventories (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Raw materials

^[1]

$ 4,464

$ 4,676

Finished goods

2,877

2,019

Total inventories

$ 7,341

$ 6,695

[1]

Note 16 - Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2023